On Friday, Allscripts Healthcare Solutions Inc (NASDAQ:MDRX)’s shares inclined 0.42% to $14.46.
The National Institutes of Health (NIH) Clinical Center, a part of the U.S. Department of Health and Human Services and the world’s largest hospital devoted exclusively to clinical investigation, used the Allscripts Sunrise(TM) platform (MDRX) to achieve Stage 7, the highest level attainable, on the HIMSS Analytics Electronic Medical Record Adoption Model(TM) (EMRAM). It is the first U.S. government health organization to achieve Stage 7.
The HIMSS Analytics EMR Adoption Model is a methodology that measures progress and cumulative capabilities of EMR systems within hospitals. There are eight stages (0-7) in the HIMSS Analytics EMR Adoption Model, and Stage 7 represents the most advanced patient record environment. Presently, only 7.8% of hospitals in the HIMSS Analytics(R) Database have reached Stage 7.
Allscripts Healthcare Solutions, Inc. provides clinical, financial, electronic health records (EHR), connectivity, hosting, outsourcing, analytics, patient engagement, and population health products and services in the United States and Canada. It operates in three segments: Clinical and Financial Solutions, Population Health, and Managed Services.
Horizon Pharma PLC(NASDAQ:HZNP)’s shares gained 1.49% to $36.85.
Horizon Pharma plc ( HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, recently declared it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number 13/665,790 (U.S. publication number 2013-0065870), entitled “Treatment of Pain with Topical Diclofenac” that covers Horizon’s U.S. approved product PENNSAID® (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%).
This Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of a U.S. patent after administrative processes are accomplished. The U.S. patent planned to issue from this application will expire July 10, 2029. After issuance, Horizon plans to list the patent in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book. This will be the eleventh U.S. patent to be listed in the Orange Book for PENNSAID 2%.
Horizon Pharma plc, a specialty biopharmaceutical company, engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally.
At the end of Friday’s trade, Norfolk Southern Corp. (NYSE:NSC)‘s shares dipped -1.71% to $84.33.
Norfolk Southern brings its Whistle-Stop Safety Train to the Carolinas this week to remind motorists and pedestrians to be safe and alert when around railroad tracks and trains.
The train, operated by Norfolk Southern with Operation Lifesaver, www.oli.org, a national rail safety public education organization, is stopping in eight cities on a three-day, 390-mile trip from Charleston, S.C., to Asheville, N.C.
Across the U.S. last year, 267 people died in highway-rail grade crossing incidents, an enhance of 16 percent contrast with 2013, and deaths due to trespassing on train tracks jumped 22 percent to 526, according to Federal Railroad Administration statistics.
In South Carolina, vehicle-train collisions resulted in three fatalities and 22 injuries during 2014, and in North Carolina five people died and 27 were injured.
Trespassing on or near railroad tracks resulted in five deaths and eight injuries in South Carolina last year, and in North Carolina 20 people died and 11 were injured.
Norfolk Southern Corporation, together with its auxiliaries, engages in the rail transportation of raw materials, intermediate products, and finished goods. As of December 31, 2014, it operated about 20,000 miles of road in 22 states and the District of Columbia. The company also operates planned passenger trains; transports overseas
Dana Holding Corporation(NYSE:DAN), ended its Friday’s trading session with 0.11% gain, and closed at $18.56.
Dana Holding Corporation (DAN) declared that its board of directors has declared a dividend on its common stock.
The board declared a quarterly dividend of $0.06 per share, payable Sept. 11, 2015, to holders of Dana common stock as of Aug. 21.
Dana Holding Corporation manufactures and sells driveline, sealing, and thermal-administration products for vehicle manufacturers in North America, Europe, South America, and the Asia Pacific. The company operates in four segments: Light Vehicle Driveline Technologies, Commercial Vehicle Driveline Technologies, Off-Highway Driveline Technologies, and Power Technologies.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
